Stock List

Search by Ticker



Regeneron Pharmaceuticals (NASDAQ:REGN)
Stock Analysis

▲ 1.25%10.17

Stock Analysis

The following stock analysis is based on 9.8 years of data (i.e. since Jun 10, 2013). All the stock history has been downloaded.

Stock Exchange

Regeneron Pharmaceuticals trades on the NasdaqGS exchange in USD dollars.


It is in the sector.

Current Status of Regeneron Pharmaceuticals

It is currently trading at $821.67 ($811.5 the previous day).


The next reporting date is in 33 days (2023 05 04).

CNN estimates profits for the upcoming quarter will be $9.82 per share ($3.0B). The current Canada / US exchange rate is 1.3511.

Over the past 12 months, $0 worth of shares have been purchased and $115611075 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 19.9% per year assuming steady exponential growth. The actual 5 year average is 13.94. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year688.1283522727318.3+ Above Average
2 year581.847261904766.5- Below Average
3 year546.4403536231968.8+ Above Average
4 year323.68539125-12.1- Below Average
5 year368.28011450382-11.8- Below Average
Regeneron Pharmaceuticals is projected by analysts to get to $891.50 within the next 12 months (8.5%), but preticted targets range from as high as $1040.00 (26.6%) and as low as $650(-20.9%).


The worst drop it has had in recent years is -53.8%. It has a shape to the stock curve, which means

Stock shape test


With an average increase of 19.9% year over year, if Regeneron Pharmaceuticals is bought at the worst time, Stockmarketizer analysts estimate it will take 32.4 months before the stock will recover to the original purchase price. The P/E value is 21.5.

Tradingview BuySell Widget

Yahoo News Feed

Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback

Wed, 29 Mar 2023 15:24:03 Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.... Read Full Article

Regeneron Shares Rally on Heavy Demand and Strong Fundamentals

Wed, 29 Mar 2023 11:43:55 Regeneron Pharmaceuticals (REGN) has been a bright spot in the market lately.... Read Full Article

Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)

Wed, 29 Mar 2023 11:00:00 Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice Approval marks second first-line indication in NSCLC and fifth indication for Libtayo in the ...... Read Full Article

Unity (UNX) Down on Disappointing Results From Wet AMD Study

Tue, 28 Mar 2023 19:25:07 Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.... Read Full Article

Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases

Tue, 28 Mar 2023 11:30:00 SOUTH SAN FRANCISCO, Calif. and TARRYTOWN, N.Y., March 28, 2023--Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases... Read Full Article

Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases

Tue, 28 Mar 2023 11:30:00 Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone paymentTARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma ...... Read Full Article

Amgen-Sanofi patent case divides makers of antibody drugs

Mon, 27 Mar 2023 22:51:01 Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines. ...... Read Full Article

UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug

Mon, 27 Mar 2023 17:28:23 UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy. UBX1325 treatment generally maintained ...... Read Full Article

UPDATE 3-U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents

Mon, 27 Mar 2023 14:35:02 Amgen Inc sought to convince the U.S. Supreme Court on Monday to revive patents on its cholesterol-lowering drug Repatha, while rival Sanofi SA urged the justices not to stifle competition for therapies to address a common health risk. The ...... Read Full Article

The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly

Mon, 27 Mar 2023 11:41:11 Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.... Read Full Article

Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court

Mon, 27 Mar 2023 10:00:00 The U.S. Supreme Court on Monday is set to hear a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a "blatant attempt" to squeeze competitors out ...... Read Full Article

Regeneron and Sanofi Look for Billions From COPD Drug

Sat, 25 Mar 2023 16:54:00 The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.... Read Full Article

Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%

Fri, 24 Mar 2023 18:29:06 Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.... Read Full Article

Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough

Fri, 24 Mar 2023 18:17:54 Growth stock Regeneron Pharmaceuticals broke out in strong volume from a flat base and 800.58 entry this week. News of the first breakthrough in a decade for a leading cause of death drove the biotech to new highs. On Thursday, phase 3 ...... Read Full Article

Wall Street Has High Hopes for These 2 Nasdaq Stocks

Fri, 24 Mar 2023 16:02:33 The stock market started out on an uncertain note on Friday, initially falling but cutting its losses in the first hour of the trading day. Two that they recently focused on were Regeneron Pharmaceuticals (NASDAQ: REGN) and Cracker Barrel Old ...... Read Full Article

Regeneron’s Asthma Drug Results Were ‘Stellar.’ Analyst Sees a Sales Bonanza.

Fri, 24 Mar 2023 13:17:00 The company and its partner Sanofi presented data from a trial of the drug as a treatment for chronic obstructive pulmonary disease.... Read Full Article

Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL

Fri, 24 Mar 2023 13:04:01 Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951... Read Full Article

ETFs in Focus on Sanofi and Regeneron's COPD Drug Data

Fri, 24 Mar 2023 12:00:12 Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.... Read Full Article

5 analyst picks of the day: Nike upped on Q3 beat | Pro Recap

Fri, 24 Mar 2023 11:47:38 Barclays upgraded Nike (NYSE:NKE) to Overweight from Equalweight and raised its price target to $154.00 from $110.00 on its belief in a high probability of margin upside. The company reported its Q3 earnings results on Tuesday, which, according to Barclays, demonstrated ...... Read Full Article

First Republic, Deutsche Bank, Chevon, Block fall premarket; Regeneron rises

Fri, 24 Mar 2023 08:07:10 By Peter Nurse... Read Full Article